US · XERS
Xeris Biopharma Holdings, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Chicago, IL 60601
- Website
- xerispharma.com
Price · as of 2024-12-31
$6.28
Market cap 1.02B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.29 | +366.4% |
| Intrinsic Value(DCF) | $23.61 | +275.96% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $8.74 | $30.24 | $0.98 | $0.00 | $0.00 |
| 2019 | $2.64 | $14.69 | $0.00 | $0.00 | $0.00 |
| 2020 | $4.81 | $80.03 | $4,722.91 | $0.00 | $0.00 |
| 2021 | $2.70 | $38.01 | $189,253.70 | $0.00 | $0.00 |
| 2022 | $1.21 | $38.71 | $179,056.18 | $0.00 | $0.00 |
| 2023 | $2.35 | $32.10 | $2,438.93 | $0.00 | $0.00 |
| 2024 | $4.24 | $29.29 | $62.14 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Xeris Biopharma Holdings, Inc.'s (XERS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.29
- Current price
- $6.28
- AI upside
- +366.4%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$23.61
+275.96% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| XERS | Xeris Biopharma Holdings,… | $6.28 | 1.02B | +366% | +276% | — | — | -11.35 | -21.01 | 3.06 | -58.75 | — | -4.11 | 81.86% | -16.57% | -27.00% | 301.32% | -20.18% | -16.99% | -9.17 | -1.01 | 1.67 | 1.12 | -14.28 | -1778.00% | 2389.00% | -2321.00% | -6.08% | -0.37 | -23.64% | 0.00% | 0.00% | 0.60% | -24.44 | -21.72 | 4.05 | -1.32 |
| ABCL | AbCellera Biologics Inc. | $3.61 | 1.08B | +1,038% | -58% | -83% | — | -7.79 | 1.18 | 15.19 | -5.71 | — | 1.30 | 100.00% | -288.98% | -194.88% | -14.47% | -29.60% | -10.78% | 0.29 | — | 11.32 | 9.21 | -0.98 | -1091.00% | 16056.00% | -689.00% | -15.25% | -2.04 | -28.78% | 0.00% | 0.00% | 0.00% | -4.09 | -5.10 | 11.82 | 2.19 |
| BCRX | BioCryst Pharmaceuticals,… | $8.75 | 1.84B | +993% | +143,402% | -35% | +1,311% | 6.86 | -15.20 | 2.07 | 4.45 | — | -15.20 | 97.82% | 38.98% | 30.16% | -88.68% | -199.20% | 52.53% | -0.10 | 4.32 | 2.06 | 1.40 | -0.22 | -38140.00% | 9410.00% | -75364.00% | 19.18% | 1.77 | -205.64% | 0.00% | 0.00% | 44.97% | 4.54 | 4.46 | 1.77 | 1.99 |
| BHVN | Biohaven Ltd. | $11.52 | 1.22B | — | — | — | — | -3.22 | 6.43 | — | -2.59 | -5.20 | 6.75 | 0.00% | — | — | -198.83% | -3466.81% | -150.03% | 0.09 | — | 3.49 | 3.17 | 0.07 | 6195.00% | — | 7519.00% | -21.53% | -3.78 | -2297.22% | 0.00% | 0.00% | 0.00% | -2.57 | -3.88 | — | 1.47 |
| CLDX | Celldex Therapeutics, Inc… | $30.09 | 2B | +2% | -54% | — | +767% | -7.71 | 3.78 | 1330.00 | -5.79 | -13.03 | 3.99 | 100.00% | -19160.00% | -17253.33% | -40.62% | -1576.31% | -37.63% | 0.00 | — | 10.49 | 10.21 | 0.10 | 5918.00% | -7863.00% | 3379.00% | -10.71% | -4.14 | -1171.86% | 0.00% | 0.00% | 0.10% | -5.15 | -6.92 | 985.84 | 16.46 |
| HRMY | Harmony Biosciences Holdi… | $28.54 | 1.64B | +155% | +609% | +1% | +178% | — | 1.91 | 1.91 | 4.41 | — | 2.13 | 77.16% | 24.00% | 18.27% | 0.00% | 43.46% | 0.00% | 0.28 | 14.23 | 3.60 | 3.46 | -2.01 | 797.00% | 2151.00% | 5909.00% | 20.94% | 1.38 | 98.30% | 0.00% | — | 14.52% | 5.40 | 3.24 | 1.30 | 4.50 |
| IMCR | Immunocore Holdings plc | $32.30 | 1.64B | +113% | -48% | -85% | — | -46.31 | 4.32 | 5.53 | 2128.75 | — | 4.32 | 97.91% | -11.34% | -8.88% | -9.58% | 14.46% | -3.42% | 0.11 | -2.77 | 4.04 | 3.80 | -1095.49 | -4804.00% | 2010.00% | -15893.00% | -0.75% | -0.03 | 5.28% | 0.00% | 0.00% | 24.39% | -24.43 | -66.96 | 2.77 | 1.37 |
| JANX | Janux Therapeutics, Inc. | $13.61 | 818.61M | +171% | -7% | -80% | — | — | 0.87 | 83.16 | 0.99 | — | 0.87 | 79.71% | -1576.67% | -1576.67% | 0.00% | -954.78% | 0.00% | 0.02 | — | 39.04 | 38.67 | 0.27 | 4297.00% | -555.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 0.00% | 0.72 | — | -11.28 | 11.29 |
| MAZE | Maze Therapeutics, Inc. | $45.59 | 2.19B | — | -84% | -77% | — | 10.06 | 2.67 | 3.14 | 5.84 | — | 2.67 | 100.00% | 34.38% | 31.18% | 50.47% | 196.80% | 33.48% | 0.14 | — | 9.76 | 9.52 | -2.80 | -10339.00% | — | -18572.00% | 14.23% | 3.67 | 261.38% | 0.00% | 0.00% | 36.28% | 6.17 | 4.75 | 2.12 | 7.53 |
| SION | Sionna Therapeutics, Inc. | $36.54 | 1.63B | — | — | — | — | -11.64 | -4.39 | — | -8.30 | -37.90 | -4.39 | 0.00% | — | — | 44.29% | 31.75% | -51.90% | -0.06 | — | 14.49 | 14.16 | 0.40 | 3071.00% | — | 1785.00% | -7.36% | -5.07 | 23.77% | 0.00% | 0.00% | 0.00% | -8.22 | -10.98 | — | -0.48 |
| VERA | Vera Therapeutics, Inc. | $40.79 | 2.86B | — | — | — | — | -8.67 | 4.29 | — | -6.55 | -12.48 | 4.29 | 0.00% | — | — | -50.71% | 1508.68% | -43.10% | 0.13 | — | 13.64 | 13.37 | 0.93 | 6945.00% | — | 7820.00% | -9.31% | -4.51 | 1156.04% | 0.00% | 0.00% | 9.22% | -6.21 | -8.10 | — | 10.20 |
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- CEO
- John Shannon
- Employees
- 394
- Beta
- 0.93
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($23.61 ÷ $6.28) − 1 = +275.96% (DCF, example).